Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enanta Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Participate in December Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Participate in Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.